The antiinflammatory effect of
764-3 was investigated in rat models of
lung inflammation and
pleurisy induced by
bleomycin intratracheal instillation and
carrageenan intrapleural cavity injection respectively. 4 mg/100 g BW.d
764-3 hypodermal injection significantly inhibited the lung inflammatory changes
in bleomycin treated rats. Compared with the experimental group, lung index,
histamine content in lung tissue and in bronchoalveolar lavage fluid (BALF), number of PMN in BALF and BALF
beta-glucuronidase activity significantly deceased in the therapeutic rats. 8 mg/100 g BW
764-3 intramuscular injection significantly inhibited the volume, number of PMN,
protein content and
beta-glucuronidase activity increase in
carrageenan-induced pleural exudate fluid. The antiinflammatory effect of 8 mg/100 g BW
764-3 was equal to that of 3 mg/100 g BW
hydrocortisone. 4 mg/100 g BW
764-3 injection significantly inhibited the increases in PMN numbers and
beta-glucuronidase activity in pleural exudate fluid. 2 mg/100 g BW
764-3 injection significantly inhibited the PMN increase in pleural exudate fluid only. 1 mg/100 g BW
764-3 injection showed no antiinflammatory effect. When
764-3 was administered orally, the antiinflammatory effect was unsatisfactory. 5 mg/100 mg BW
764-3 significantly inhibited the volume, number of PMN,
protein content and
beta-glucuronidase activity of
carrageenan-induced pleural exudate fluid. 2.5 mg/100 g BW
764-3 significantly inhibited the volume and
protein content increases in pleural exudate fluid. But 3.5 mg/100 g BW
764-3 showed no antiinflammatory effect. The authors indicate that the antiinflammatory effect of orally administered
764-3 was not stable.